Subscribe to Updates

    Get the latest creative news from eReadIT about money, health, lifestyle and more.

    loader

    Email Address*

    Name

    Facebook X (Twitter) Instagram
    Trending
    • Focused ultrasound aimed deep into the brain may ease delusions, pilot study suggests
    • How Reverse-Grip Lat Pulldowns Helped Jay Cutler Build an Even Wider Back
    • Nick Walker Shares His Pre-Arnold Classic Upper-Body Workout
    • 5 Pain-Free Arm-Building Alternatives to Barbell Curls
    • How the Film ‘Anatomy of a Fall’ Can Help You Build Empathy
    • When Being the Strong One Makes It Hard to Ask for Help
    • Finding Solace and Comfort in Listening to Trees
    • Did a Narcissistic Boss Cost You Your Career?
    EREADIT
    Write for Us
    • Write for Us
    • Local News
    • World
    • Politics
    • Money
    • Crypto
    • Technology
    • Sports
    • Entertainment
    • Game
    • Health
    • Lifestyle
    • Watch
    • Travel
    • Podcasts
    EREADIT
    Home»Health»Focused ultrasound aimed deep into the brain may ease delusions, pilot study suggests
    Health

    Focused ultrasound aimed deep into the brain may ease delusions, pilot study suggests

    BY Eric W. Dolan November 19, 2026No Comments0 Views
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

     ​

    A small pilot trial suggests that aiming gentle, noninvasive sound waves deep into the brain may temporarily ease delusions in adults living with chronic psychosis. In a randomized comparison against a fake stimulation session, 10 outpatients who received 10 minutes of low-intensity focused ultrasound directed at a deep brain hub showed a moderate drop in delusion severity without experiencing serious side effects. The preliminary findings were published in npj Acoustics.
    Schizophrenia and related conditions such as schizoaffective disorder are chronic psychiatric illnesses that alter how a person perceives reality, thinks, and relates to the world around them. Two hallmark psychotic symptoms are hallucinations, such as hearing voices when no one is speaking, and delusions, which are fixed beliefs that persist even when contradicted by everyday evidence. Standard antipsychotic medications quiet these symptoms for many patients, yet a substantial number continue to experience distressing delusions despite ongoing drug treatment.
    Brain-imaging studies link psychosis to abnormal signaling along a deep loop of neural pathways connecting the cerebral cortex, the brain’s outer layer, with central relay structures called the striatum, the globus pallidus, and the thalamus. Tucked near the middle of the brain beneath the cortex sits the globus pallidus interna, a paired cluster of nerve cells within the basal ganglia that serves as a primary output gate sending dopamine-influenced signals to the thalamus. Beyond helping coordinate physical movement, this pathway helps filter incoming information so the brain can judge which everyday events deserve attention.
    In a 2023 brain-imaging study conducted by members of the same research group, unmedicated patients experiencing a first episode of schizophrenia showed unusually heightened communication between the right anterior globus pallidus interna and the dorsal anterior cingulate gyrus, a frontal brain region involved in weighing what demands attention. Stronger signaling along that link tracked with worse psychotic symptoms and predicted how well patients responded to eight weeks of medication, pointing to the right globus pallidus interna as a candidate for brain stimulation.
    Targeting a deep brain hub without incisions
    Reaching a structure buried roughly six centimeters beneath the brain’s outer membrane has historically posed a steep technical challenge. Standard noninvasive neuromodulation tools, such as magnetic coils held against the scalp, mainly influence tissue near the brain’s surface, whereas modulating the globus pallidus interna without destroying tissue has traditionally required neurosurgery to implant electrodes, as done in movement disorders like Parkinson’s disease.
    Low-intensity transcranial ultrasound stimulation works differently: a curved acoustic device rests against the scalp and transmits focused, relatively low-frequency ultrasound waves through the skull to converge on a narrow, elongated zone of deep tissue, temporarily shifting nerve cell excitability without incisions or tissue heating.
    To test whether this noninvasive technique could influence psychotic symptoms by targeting the right globus pallidus interna, Wei Qi collaborated with senior colleagues Donald C. Goff and Shy Shoham at NYU Grossman School of Medicine. Goff is the Marvin Stern Professor of Psychiatry and vice chair for research in the Department of Psychiatry at NYU Grossman School of Medicine and directs the Nathan S. Kline Institute for Psychiatric Research, while Shoham is a professor in the Department of Neuroscience at NYU Grossman School of Medicine and co-director of its Tech4Health Institute.
    “Many people with schizophrenia continue to have delusions despite antipsychotic medication, and there are few options for them once medications have failed,” Qi, a clinical assistant professor in the Department of Psychiatry at NYU Grossman School of Medicine and a psychiatrist and researcher at Rockland Psychiatric Center and the Nathan S. Kline Institute for Psychiatric Research, told PsyPost. “Brain imaging and decades of research in movement disorders point to the globus pallidus interna, a deep hub in a circuit thought to help the brain decide which experiences feel important. Until recently, the only way to reach such a deep target was surgery. Low-intensity focused ultrasound allowed us to test, without surgery, whether modulating this circuit could affect psychotic symptoms.”
    Earlier human experiments laid the groundwork for testing this approach in psychosis. First, a 2021 brain-imaging study of healthy volunteers demonstrated that aiming low-intensity ultrasound at the left globus pallidus reduced blood-oxygenation signals linked to neural activity both inside that deep hub and across connected brain networks during stimulation.
    More recently, a clinical trial of adults with mood, anxiety, and trauma disorders found that focused ultrasound lowered activity in the left amygdala compared to a sham procedure, and a three-week course of repeated sessions produced moderate-to-large drops in depression, anxiety, trauma symptoms, and overall emotional distress. Only two previous studies had tested ultrasound stimulation in schizophrenia, one reporting an immediate drop in hallucinations after targeting other striatal areas in three patients and the other targeting the outer prefrontal cortex for social withdrawal and blunted emotion, leaving the right globus pallidus interna unexplored.
    How the randomized crossover trial worked
    Before treating patients, the engineering team calibrated their custom 350-kilohertz ultrasound device in a water tank and across the temple bone of two human skull specimens. Although passing through skull bone absorbed 83 to 88 percent of the acoustic intensity, the beam maintained a cigar-shaped focal zone measuring 5.6 millimeters wide by 27.5 millimeters long. Introducing the skull shifted the beam’s focus by an average of one millimeter, and estimated pressure and heating inside the brain remained well within international safety limits.
    The researchers registered the trial on ClinicalTrials.gov in November 2022 ahead of recruitment, made the full protocol and analysis plan available on the registry alongside publicly posted analysis code, and kept individual patient records restricted to protect medical privacy. Designed as an initial pilot study to assess safety, tolerability, and preliminary symptom signals, the trial screened 15 adults and enrolled 11 outpatients aged 18 to 55 with schizophrenia or schizoaffective disorder and at least moderate psychotic symptoms between May 2023 and January 2024.
    One volunteer withdrew after an initial brain scan, leaving 10 participants who completed every stage of the study. Those 10 participants had an average age of 37.5 years, were split evenly between men and women, and included four African American, three Asian, one Caucasian, and two adults who identified as mixed race or another category.
    Before enrolling, every participant had to pass a psychiatrist’s evaluation of decision-making capacity and score 100 percent on a 10-item quiz covering the study’s procedures, risks, and alternatives. Six participants were taking stable doses of antipsychotic medication (paliperidone, aripiprazole, quetiapine, or haloperidol), and four had been off antipsychotic drugs for at least four weeks; all 10 maintained that pre-enrollment status throughout the trial.
    Using a randomized crossover design, each volunteer attended two sessions spaced one week apart: one active ultrasound session and one sham session, delivered in random order so that neither the participants nor the clinical raters knew which session was active. Each participant first underwent a structural MRI scan to map their individual brain anatomy. During the visits, foam blocks held the seated participant’s head steady while optical tracking cameras monitored reflective markers on both the head and the ultrasound device in real time. Coupled to the scalp with ultrasound gel and a water-filled membrane, the device was aimed directly at the right globus pallidus interna.
    During the 10-minute active session, the system delivered brief ultrasound pulses in ten cycles of 30 seconds on and 30 seconds off, actively transmitting sound for 5 percent of each 30-second window. During the sham session, the equipment ran at identical settings, but an air layer inside the water cushion blocked the ultrasound waves from entering the skull.
    Participants completed brief questionnaires rating delusions and auditory hallucinations at six points around each visit: beforehand, during stimulation, immediately afterward, one hour later, one day later, and seven days later. They also took the Montreal Cognitive Assessment, a short screening test of memory and thinking skills, before and one hour after each session, while clinicians tracked physical and psychiatric side effects and suicidal thoughts through day seven. Resting-state functional MRI scans were collected before and after each session as well, though technical issues later prevented those brain scans from being analyzed.
    Moderate reductions in delusions and an unexpected delay
    Across all post-baseline assessments combined, delusion scores declined by an average of 1.2 points after active ultrasound stimulation, compared with a 0.4-point average increase after sham stimulation, against session-baseline averages ranging from roughly 12 to 16 points. In the primary statistical model accounting for assessment timing and session order, active ultrasound was associated with an estimated 1.56-point greater reduction in delusion scores than sham, corresponding to a moderate effect size (Cohen’s d = 0.68). At the individual level, symptom trajectories varied considerably from person to person across the two-week crossover sequence.
    “The difference between real and sham stimulation was moderate in size and statistically robust for a study this small,” Qi noted. “Still, with only 10 participants, the estimate is imprecise, and the benefit beyond the first days is unknown. Larger, longer trials are needed to know how big and how lasting the effect really is.”
    Changes in auditory hallucination ratings across the post-baseline assessments were not statistically significant between active ultrasound and sham, in contrast to the immediate drop reported in the earlier three-patient trial targeting other regions of the striatum. Differences on the cognitive test one hour after stimulation fell just short of statistical significance, with scores rising an average of 0.2 points after real ultrasound and dipping 1.0 point after sham.
    After finishing the study, six of the 10 participants accurately guessed which session was real, a rate not statistically distinguishable from chance, and follow-up checks indicated that guessing accurately was unrelated to delusion change. Evaluated descriptively rather than through a formal statistical test because of the small sample, session-baseline scores also showed no consistent pattern of carryover from one week to the next.
    No serious adverse events occurred in either condition. Seven of the 10 participants reported at least one mild, temporary symptom increase after active ultrasound, while all 10 reported at least one side effect after sham stimulation. Reported complaints included brief fatigue, headache, mild stomach discomfort, and minor upticks in delusions or hallucinations, along with a single moderate report of feeling detached from surroundings after a sham session.
    Asked what the average person should take from the trial, Qi said, “It’s an encouraging first step, but it is not yet a treatment.”
    An exploratory analysis of individual time points hinted at an unexpected temporal pattern, although the pilot trial was not designed to confirm effects at isolated days. Rather than peaking during the 10-minute stimulation and fading right away, the estimated gap in delusion reduction between active and sham sessions stood at 1.90 points one day afterward and widened to 2.70 points seven days afterward. However, the day-one difference did not reach statistical significance even before adjustment, and none of the five post-baseline comparisons remained statistically significant after adjusting for multiple testing.
    To explain that gradual pattern, the authors propose that pulsed ultrasound may initiate lasting neuroplastic adjustments in glutamate-related signaling within the right globus pallidus interna and its connected cortical loop, consolidating over days until the brain’s tendency to assign undue importance to everyday experiences, known as aberrant salience, subsides. They note that durable responses have appeared in other ultrasound studies of deep brain hubs, including a 2024 clinical study of chronic pain where a single session targeting a pain-processing region eased pain through day seven, and a 2023 case report on severe treatment-resistant depression where deep-brain ultrasound preceded remission lasting up to 44 days.
    “Seeing an effect on psychosis wasn’t a surprise, because that was our hypothesis,” Qi explained. “The pattern was surprising. We expected an immediate effect that would fade, as with many forms of brain stimulation.”
    “Instead, the improvement seemed to build over the following days,” Qi added. “That suggests ultrasound may trigger lasting changes in how the circuit adapts, rather than acting like an on/off switch.”
    Caveats and next steps for ultrasound research
    There are a few things to keep in mind when weighing these early findings. Testing a single 10-minute session in 10 outpatients over one week makes this a preliminary proof-of-concept study rather than confirmation of clinical efficacy. The authors note that the statistical effect size for delusions (0.68) is comparable to the 0.47 average reported across placebo-controlled trials of antipsychotic medications, yet the brief questionnaire used at the six check-ins was built to track moment-to-moment fluctuations rather than clinically meaningful recovery. As a result, it remains uncertain how much an average 1.56-point drop on a roughly 12-to-16-point baseline translates into noticeable relief in daily life.
    Qi also drew a line between the experimental technique and treatments already in clinics. “This is not a cure, and it’s not a replacement for medication; all participants stayed on their usual treatment,” Qi emphasized. “It is also different from the high-intensity focused ultrasound approved for tremor, which destroys a small area of tissue.”
    “Our approach uses much lower energy to change brain activity temporarily,” Qi continued. “Finally, this treatment isn’t available outside research. It is not ready for clinical use.”
    Several technical hurdles also limit what the pilot data can establish about how the stimulation worked. Because technical problems rendered the resting-state functional MRI scans uninterpretable, the researchers could not confirm that the ultrasound beam altered neural activity inside the right globus pallidus interna as intended. Acoustic dosing was also calibrated using two human skull specimens rather than tailored to each volunteer’s skull thickness, which can affect how much sound energy reaches deep tissue. In addition, blinding was checked only with a two-choice guess at the end of the study; with six of 10 participants guessing accurately, expectation effects cannot be excluded, and the authors state that the trial should not be considered fully double-blinded.
    “We aim to run a larger trial with repeated sessions and longer follow-up, to test how durable and reproducible the effect is,” Qi stated. “We also want to measure how ultrasound changes the underlying circuits involved in delusions using functional MRI.”
    Looking back on the pilot trial, Qi credited the interdisciplinary partnership behind the study, adding, “This study was a team effort across psychiatry, engineering, and statistics, and I’m grateful to my co-authors, our participants, and the funding foundations (Doris Duke Fund and Brain & Behavior Research Foundation) for their support.”
    The study, “Transcranial ultrasound stimulation of the right globus pallidus interna in schizophrenia: A randomized, sham-controlled pilot study,” was authored by Wei Qi, Alon Gilad, Michele Santacatterina, Spencer Brinker, Gillian Capichioni, Fumika Ando, Shy Shoham, and Donald C. Goff. 

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    How Reverse-Grip Lat Pulldowns Helped Jay Cutler Build an Even Wider Back

    November 19, 2026

    Nick Walker Shares His Pre-Arnold Classic Upper-Body Workout

    November 19, 2026

    5 Pain-Free Arm-Building Alternatives to Barbell Curls

    November 19, 2026

    Comments are closed.

    Weather

    Trending

    Kristina Bogic On ‘The Body,’ Anya’s Sexuality, & Season 2

    November 12, 2026

    Spain’s king and queen attend memorial service for rail crash victims

    November 10, 2026

    Transport workers in Chile block highways in protest over surging fuel prices

    November 11, 2026

    Jensen Huang scandal fuels bipartisan push to block AI chip sales to China

    November 18, 2026

    Subscribe to Updates

    Get the latest creative news from eReadIT about money, health, lifestyle and more.

    loader

    Email Address*

    Name

    eReadIT

    eReadIT enjoys delivering you valuable news that will educate, entertain, and enrich the lives of our readers from around the world and throughout your day. To stay up to date on the latest news check out our site.

    • Local News
    • World
    • Politics
    • Money
    • Crypto
    • Technology
    • Sports
    • Entertainment
    • Game
    • Health
    • Watch
    • Travel
    • Lifestyle
    • Podcasts
    • RSS
    • Contact
    • Privacy Policy
    • Terms & Conditions

    EREADIT LLC
    2400 Herodian Way SE, #220
    Smyrna, Georgia 30080
    Email Us : info@ereadit.com

    Copyright © 2026 EREADIT. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.